HAO

BEIJING, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (NASDAQ: HAO; "we" or the "Company"), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0000001 per share (the "Class A Ordinary Shares") and Class B ordinary shares, par value $0.0000001 per share (the "Class B Ordinary Shares"), at a ratio of 1-for-20. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on August 14, 2026.

BEIJING, July 14, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), a Beijing-headquartered online marketing solutions provider specializing in one-stop digital marketing services for the health and wellness industry, today announced the signing of a strategic cooperation framework agreement with NOVA MEDIA, a technology company with expertise in AI digital humans and generative AI.

New York, July 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $4 million for its client Haoxi Health Technology Ltd (NASDAQ: HAO) (the "Company"), a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients.

BEIJING, July 10, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Ltd (NASDAQ: HAO) (“Haoxi” or the “Company”), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 10,000,000 of the Company's Class A Ordinary Shares, par value $0.32 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.40 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.33 per share.

BEIJING, May 19, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (NASDAQ: HAO; “we” or the “Company”), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0025 per share (the “Class A Ordinary Shares”) and Class B ordinary shares, par value $0.0025 per share (the “Class B Ordinary Shares”), at a ratio of 1-for-128.

BEIJING, May 11, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Ltd (NASDAQ: HAO) (“Haoxi” or the “Company”) today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of approximately $6.5 million of the Company's securities, including 9,000,000 Class A ordinary shares, par value $0.0025 per share (the “Shares”) and 16,999,998 pre-funded warrants, at a purchase price of $0.25 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.0026 per share.